top of page


Gaddiel Galarza-Muñoz, PhD

Co-founder and President (full time)

  • LinkedIn
  • ABS Principal Investigator -- awarded $2.7M in grants for ABS

  • Researcher in the discovery of sIL7R pathway and inventor of sIL7R-targeting drugs

  • Adjunct Assistant Professor, Neurology, University of Texas Medical Branch (UTMB)

Dr. Gaddiel Galarza-Munoz completed his PhD degree in Biology with emphasis in Neuroscience at the University of Puerto Rico and postdoctoral training in Molecular Genetics and RNA Biology at Duke University and the University of Texas Medical Branch. Currently, Dr. Galarza-Munoz is Co-founder and President of Autoimmunity BioSolutions (ABS), a preclinical biotechnology company developing immune-modulators for treatment of autoimmune diseases and cancer. He is also adjunct assistant professor in Neurology at the University of Texas Medical Branch. Based on the research he conducted during his post-doctoral training in the laboratory of Dr. Mariano A. Garcia-Blanco, Dr. Galarza-Munoz co-founded ABS and invented ABS lead therapeutic products under development. Dr. Galarza-Munoz is Principal Investigator in six NIH SBIR/STTR grants awarded to ABS totaling $2.7M and holds three issued patents on technologies around the sIL7R pathway.

Mariano Garcia-Blanco, MD, PhD

Co-founder and Chair, SAB

  • LinkedIn
  • Chair & Professor, Microbiology, Immunology & Cancer Biology, University of Virginia

  • Founder of five companies: Intronn (later VIRxSYS), Veri-Q, SABio, ABS, and Emervax

  • Member of American Academy of Arts & Science with over 190 peer-reviewed publications

Mariano A. Garcia-Blanco received his MD and PhD in Molecular Biophysics and Biochemistry from Yale University and completed a fellowship at the Massachusetts Institute of Technology. Professor Garcia-Blanco has been in the faculty at Duke University, Duke-NUS Medical School in Singapore, and the University of Texas Medical Branch. Currently he is the F. Palmer Weber Medical Research Professor and Chair of the department of Microbiology, Immunology and Cancer Biology at the University of Virginia. He is an expert in RNA biology and RNA virology who has been continuously funded by the National Institutes of Health since 1991, has published more than 190 articles, and has mentored more than 60 doctoral and postdoctoral trainees. Professor Garcia-Blanco was elected to the Association of American Physicians (2011), fellow of the American Academy for the Advancement of Science (2011), fellow of the American Academy of Microbiology (2013), and to the American Academy of Arts and Sciences (2022).

Autoimmunity BioSolutions_Introductory D
Thomas Forest Farb-Horch

Co-founder, Treasurer and Board Director

  • LinkedIn
  • Co-founder, President & CEO, Thrive Biosciences

  • Senior life science executive & serial entrepreneur (>40 years)

  • Founder of 18 companies, 7 multi-billion exits, and >$750 million in early-stage financing

Mr. Thomas Forest Farb-Horch has been involved in founding of 18 pharmaceutical, biotech, medtech, software, and AI companies, 7 of which have been unicorns. Currently he is CEO and Co-Founder of Boston-based Thrive Bioscience, commercializing instruments and software for imaging, analytics, and automation of cell culture, cell-based research, and cell therapeutics. In addition to his full-time position at Thrive, he is currently on the Board of Directors of two companies he also co-founded: Autoimmunity BioSolutions, an immunotherapy company targeting a novel autoimmune pathway, and Emervax, an RNA vaccine company for numerous emerging infectious diseases with pandemic potential. He is also on the Board of Directors of a Boston-based Greentech and life sciences business incubator, InnoVentures Labs.   Tom has founded and/or served on the Boards of Exact Sciences (NASD: EXAS), Fair Isaac (NYSE: FIC), Redwood Trust (NYSE: RWT), HNC Software (acquired by Fair Isaac), Retek Systems (acquired by Oracle), and Saf-T-Med (acquired by Becton Dickinson), among others. Tom has served as President or in senior management positions at numerous companies, including President and COO of Indevus Pharmaceuticals (acquired by Endo), CFO and VP of Corporate Development at Cytyc (acquired by Hologic), and Executive Director at the Trust for Science and Technology in San Juan, Puerto Rico. Tom has also been a Trustee for several non-profit organizations, including Dana Farber Cancer Institute, Asia America Chamber of Commerce, Concord Museum, and The Fenn School. Mr. Farb is a graduate of Harvard University.

Pic-Takashi Kiyoizumi_edited.jpg
Takashi Kiyoizumi, MD, PhD
  • LinkedIn

EVP, Business Development and Board Director

  • Managing Director, Kiyoizumi Advisory LLC; Founder & former CEO, MediciNova; Angel investor

  • Senior life science executive & serial entrepreneur (>40 years)

  • Significant BD Experience: >25 strategic & licensing deals

Dr. Kiyoizumi has over 40 years of experience in life sciences, and is also an angel investor, entrepreneur, and mentor. Prior to his executive position at Autoimmunity BioSolutions, Dr. Kiyoizumi was the founder and CEO of MediciNova (NASDAQ: MNOV), and president and CEO of Tanabe Research Laboratories, a U.S. affiliate of Mitsubishi Tanabe Pharma. As the managing director of Kiyoizumi Advisory, LLC, Dr. Kiyoizumi provides life science companies and venture capital firms with in-depth analyses and recommendations on strategic, business development or investment matters. He is also the executive manager of the Japan Forum for Innovation and Technology (JFIT) at the University of California, San Diego. JFIT aims to foster new collaboration and innovation between San Diego and Japan. On the investment side, Dr. Kiyoizumi is a member of NuFund Venture Group and BioPacific Investors. Dr. Kiyoizumi received his M.D. and Ph.D. at the Keio School of Medicine in Tokyo, and his MBA from the MIT Sloan School of Management. He is a Guest Professor at the School of Health Innovation, Kanagawa University of Human Services in Kanagawa, Japan, and also served as a volunteer physician with Project HOPE.

Bobby W. Sandage Jr., PhD
  • LinkedIn

Senior Advisor, Drug Development & Regulatory

  • CEO & President, Euclises Pharmaceuticals; Managing Director or Partner of two Venture Funds

  • Senior life science executive, serial entrepreneur, and venture capital investor (>40 years)

  • Significant Regulatory Experience: >14 approved drugs

Bobby W. Sandage, Jr., Ph.D. has over 40 years of experience in the pharmaceutical industry in drug development and senior management and over 10 years in venture capital investing and currently holds positions in the St. Louis area as Managing Director of the Paula and Rodger Riney Foundation and Lightchain Capital, a venture fund, and is a General Partner in Cultivation Capital Life Sciences Fund II, also a venture fund. He is the acting CEO for one of the current portfolio companies, Euclises Pharmaceuticals and Interim Head of Development for another current portfolio company, AI Proteins. Previously Dr. Sandage was President and Chief Executive Officer of Coronado BioSciences, Inc. (NASDAQ: CNDO), an immunotherapy company where he took the company public in 2011. Prior to that, he was Vice President of Covidien (Mallinckrodt) Pharmaceuticals’ oncology research and development program. For 19 years, Dr. Sandage was the Chief Scientific Officer and Executive Vice President of Research and Development, Quality and Manufacturing at Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV) (successor to Interneuron Pharmaceuticals, Inc.), which was acquired by Endo Pharmaceuticals in 2009. Prior to Indevus, he held senior drug development positions at DuPont Merck Pharmaceutical Company, DuPont/American Critical Care, Merrell Dow and Dow Pharmaceuticals. Dr. Sandage has extensive experience guiding numerous life sciences companies as a Member of the Board of Directors of NextRNA (Lead Director), Microbial Machines, AI Proteins, Immunophotonics (chairman), Geneoscopy and Endevica Bio. He was previously Board Director at Mateon (NASDAQ: MATN), Arch Oncology, Gentium S.r.l. (NASDAQ: GENT), Osteologix, Inc. (NASDAQ: OLGX), and Genta (NASDAQ: GNTA). Dr. Sandage received his undergraduate degree in Pharmacy from the University of Arkansas and his Ph.D. in Clinical Pharmacy from Purdue.

Peter D. Weinstein, PhD, JD
  • LinkedIn

General Counsel

  • Founder & CEO, Entralta

  • Senior life science counsel and executive (>20 years)

  • Significant Corporate and Patent Law Expertise

Peter D. Weinstein, Ph.D., J.D. is the founder and Chief Executive Officer of Entralta. Dr. Weinstein counsels clients in all aspects of Intellectual property, transaction and corporate law. He received his Juris Doctorate degree at Boston College Law School. Dr. Weinstein is a registered patent attorney and is licensed to practice law in California and Texas.   Previously, Dr. Weinstein worked for many years as Senior Patent Counsel at Baxter Healthcare Corporation where he was responsible for managing legal and intellectual property matters for Baxter’s major hemophilia products like Advate® and major research and development programs in hemophilia. Prior to Baxter, Dr. Weinstein worked in the San Diego Offices of the law firms of Brobeck, Phleger & Harrison, and Fish & Richardson where his practice focused on the management and prosecution of patent portfolios for biotech and high-tech companies and patent and general civil litigation. During law school, he worked full-time as a patent agent in the Boston Office of Goodwin Procter. Dr. Weinstein also worked as an Examiner at the United States Patent and Trademark Office followed by a stint as a Senior Scientist at a biotech company where he was involved in developing vaccines and other therapeutics for the treatment of infectious disease in large animals.   Dr. Weinstein received his Ph.D. in Biology with an emphasis in Immunology from the University of Pennsylvania. Following receipt of his Ph.D., Dr. Weinstein worked as a Research Fellow, first at the National Institutes of Health in Bethesda, Maryland and then at the United States Army Medical Research Institute of Infectious Disease in Frederick, Maryland where he investigated the molecular development of antibody diversity and developed vaccines.

bottom of page